Navigation Links
The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
Date:6/3/2008

Quarterly Reports Utilize Strategic Intelligence and Competitive Analysis from Thomson Reuters to Analyze Promising Drugs Changing Clinical Phase, Leading Sources of Information on Medical Research and the U.S. Generics

Market

LONDON and PHILADELPHIA, June 4 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of the Pharma Matters reports covering the time period October-December 2007. The Pharma Matters quarterly report series was launched two years ago and covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).

Who is Making the Biggest Splash? -- This report is a Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the listed 15 organizations that have made the biggest impact as the leading sources of information on medical research from October-December 2007 are:

1. Bristol-Myers Squibb

2. Eli Lilly

3. Pfizer

4. GlaxoSmithKline

5. AstraZeneca

To see the complete list, as well as analysis and methodology, click to read the full report: http://thomsonpharma.com/media/pdfs/tpqr/making-a-splash-dec2007.pdf

The Ones to Watch -- A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on the strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q4 2007, the top five of the most promising drugs launched or receiving approval were:

DRUG DISEASE COMPANY

ATryn(R) Hereditary antithrombin GTC Biotherapeutics/

deficiency LEO Pharma

OncoVAX(R) Colon cancer, melanoma, Vaccinogen

renal cell carcinoma

Ixempra(TM) Breast cancer Bristol-Myers Squibb

Isentress(TM) HIV-1 infection Merck & Co

Perforomist(TM) Chronic obstructive Dey

Inhalation Solution pulmonary disease

More analysis, as well as information on drugs entering clinical Phases I, II and III, are available in the full report: http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/tp_qr_oct- dec_07.pdf (Due to length of URL, Please copy and paste link into browser. Remove the space if one exists.)

Movers and Shakers -- Introduced in mid-2007, this report is the newest in the Pharma Matters series and covers the U.S. generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q4 2007 report includes:

-- 2007 was a year of unprecedented competition in the US generics market,

driven primarily by the number of new players entering the Generics

field.

-- ANDA approvals climbed to a record of more than 480, an increase from

365 the previous year. Paragraph IV patent challenges also continued at

a fierce pace.

-- Forty different drug products were exposed to paragraph IV challenges

for the first time in 2007, almost a doubling of the 24 in 2006.

-- During the last quarter of 2007, the largest number of ANDA approvals

went to US-based companies.

-- In the same time period, nine India-based companies received a total of

21 approvals, putting India in second place.

-- In the previous quarter, Indian-based companies were the leaders in

terms of ANDA approvals with 51, while US-based companies received a

total of 44 approvals.

To learn more about companies making their mark on the U.S. generics market, click on this link to read the full report: http://scientific.thomson.com/thomsonpharma/media/pdfs/tpqr/movers_shakers_ oct -dec07.pdf (Due to length of URL, Please copy and paste link into browser. Remove the space if one exists.)

To sign up for the Thomson Reuters Pharma Matters series of publications visit: scientific.thomson.com/pharma/forms/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE The Scientific business of Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Expands Global Distribution Network
2. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
3. The International Rett Syndrome Foundation Names Antony Horton Ph.D. Chief Scientific Officer
4. Kewaunee Scientific Corporation Increases Quarterly Dividend
5. Texas Jury Awards $250 Million Patent Infringement Verdict Against Boston Scientific in Balloon Catheter Lawsuit
6. NIDCR strategies for future scientific success
7. Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress
8. Novadaqs SPY System was Topic of Best Poster in Scientific Session at AUA
9. ASINEX and CDD Team up for Open Access Data for the Scientific Community
10. Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence
11. 2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology: